

Towards Industry 4.0: Development of a Smart Bioprocessing Platform Integrating Real-Time Monitoring and Advanced Process Control for Autologous Cell Therapy

P Statham¹, D Marginean¹, N Thompson¹, M Filipiak¹, S Wadud¹, C Pararasa¹, C Nerincx¹, J Churchwell¹, C Szybut¹, C O'Grady¹, N Goddard², A Toufexi², K Daldoul², L Teixeira², M Werner Sunderland², M Salm², P Becker², JC Garcia-Cañaveras³, MI Alcoriza-Balaguer³, O Wohlenberg⁴, S Dienemann⁴, A Lahoz³, D Solle⁴, M Mata¹, V Di Cerbo¹

Cell and Gene Therapy Catapult, London, United Kingdom¹, Achilles Therapeutics Limited, London, United Kingdom², Instituto de Investigación Sanitaria La Fe, Valencia, Spain³, Institut für Technische Chemie, Leibniz Universität, Hannover, Germany⁴


CATAPULT

Cell and Gene Therapy

saadat.wadud@ct.catapult.org.uk


Clinical adoption and patient's accessibility of autologous immunotherapies remain hindered by the lack of efficient, consistent, cost-effective, and scalable manufacturing processes. To address this bottleneck, an international EU-funded consortium is developing a first-in-class, smart bioprocessing platform for personalised autologous cell therapies, integrating in-line process analytical technologies and advanced process control systems. Using a clinical-stage tumor-infiltrating lymphocytes (TILs) manufacturing process as a model, a static baseline process in the G-Rex system was adapted to a dynamic, stirred-tank reactor (STR) system. In addition, metabolomic profiling of spent media identified ~50 metabolites with a significant effect on cell expansion. Focusing on three key metabolites, alongside agitation speed and dissolved oxygen as critical process parameters (CPPs), we conducted design of experiment (DoE) studies using the STR systems, with integration of Raman probes, as an online process analytical tool. Based on these results, subsequent work will implement real-time monitoring and model predictive control strategies leveraging chemometric and mechanistic models to enhance process consistency and performance.

GRex® to STR Adaptation




- Exemplar autologous TIL-DC co-culture process with subsequent reactive TIL expansion.
- Prior art suggest static conditions were thought to be **needed for higher reactivities**.
- Agitated systems are **controllable**. pH, DO, temperature, metabolite controls can facilitate improved autologous process performance.

Successful Translation to Agitated System




- Successful translation of **static process to STR** and subsequent investigation of **intermittent versus constant agitation**.
- These studies showed **constant, high RPM led to higher T-Cell expansion and reactivity** than the initial static.

Maintenance of CD8+ Reactivity in Agitated System



Critical Process Parameter/Biomarker Screen



- T-Value is an **indicator of effect significance**.
- Above Bonferroni limit means clearly significant.
- Above t-value limit means effects are possibly important.


- p-Values indicate output from **Robust Rank Aggregation** to prioritise metabolites into a universally ranked list.

- Two steps done in parallel.
- **7 CPPs were screened** over 2 screening runs.
- These resulted in identifying **2 process parameters** critical to T-Cell expansion and reactivity.
- Biomarker screen led a **shortlist of 57 metabolites**.
- These were narrowed to **3 identifiable by Raman, and interesting for T-Cell metabolism**.

T-Cell Culture Design Space Exploration

- The DoE was a 5-level, central composite design, consisting of **32 STR vessels** utilising **parameters identified in the previous screens**.
- Aim was to introduce significant process perturbations and measure their effects expansion of CD3+, reactive CD4+, and reactive CD8+.
- **Raman spectroscopy** data was collected for generation of a PAT chemometric model.

DoE Model Generation




Optimal Parameter Determination


Metabolite A	Metabolite B	Metabolite C	CPP 1	CPP 2	Response	Response Prediction	Desirability
↑	↑	↓	↑	↓	↑ CD3+ Fold Expansion	403-fold	0.653
↓	↑	↓	↑	↑	↑ CD4+ Fold Expansion	469-fold	0.224
↓	↑	↓	↑	↑	↑ CD8+ Fold Expansion	986-fold	0.696
↓	↓	↑	↑	↑	↑ % Reactivity	NA	0.462

- DoE model predicted ideal operating conditions for T-Cell bioprocessing.
- Model predicts that a combination of **high metabolite A and high metabolite B** will result in high CD3+ fold-expansion.
- Model also predicts that **high metabolite C** will increase % reactivity.

Generation of High R² Chemometric Models




- **800 Raman spectra** were selected as training data for chemometric models.
- These models will be utilised for a model for predictive control as a strategy to predict process output based on real-time monitoring of CPPs.



Future Work:

- Generate and integrate **chemometric and bioprocess models** for use in real-time monitoring and control with healthy and patient material.
- Models will be tested for real-time monitoring of the CPPs and metabolites in future runs.
- Readings will inform a control system to automatically supplement feeds with metabolites to maintain an optimal concentration throughout the process.



- Perturbations allowed **coverage of a large design space**.
- Conditions were used to elicit both **positive and negative responses**.
- Large range of responses allows for **more robust bioprocess and chemometric models**.
- Yield and reactivity improvements indicated **optimal process conditions** leading to 450-fold expansion.